ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2318

Practice Patterns and Barriers in the Referral, Management and Monitoring of Axial Spondyloarthritis: Insights from an Online Survey of Rheumatologists

Khalid Alnaqbi1, Mohammed Alaswad2, Tariq Al Araimi3, Amr Mahmoud4, Samar Al emadi5, Hanan Al Rayyes6, Khuloud Mohammed7 and Xenofon Barliakos8, 1Sheikh Tahnoon Medical city, Al Ain, United Arab Emirates, 2Faculty of Human Medicine, University of Hama, Hama, Syria, 3Royal Hospital, Muscat, Oman, 4Department of Pharmacology, Pharmacy Program, Oman College of Health Sciences, Muscat, Oman, 5Hamad medical corporation, Doha, Qatar, 6Department of Medicine, Prince Sultan Military Medical City, Riyad, Saudi Arabia, 7Farwaniya Hospital, Kuwait, Kuwait, 8Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany

Meeting: ACR Convergence 2025

Keywords: Access to care, Measurement Instrument, Outcome measures, spondyloarthritis, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: There is a dearth of literature exploring challenges faced by rheumatologists in the referral, diagnosis, management, and monitoring of patients with suspected axial spondyloarthritis (axSpA) worldwide. Our study aims to understand such challenges faced by rheumatologists in the Gulf countries.

Methods: A cross-sectional online survey was conducted among practicing rheumatologists in six countries using 35-close ended questions. Items underwent refinement using a sensibility assessment framework and were pilot-tested among 12 rheumatologists, and followed international survey reporting guidelines. The survey assessed demographic characteristics, referral patterns, diagnostic features, monitoring practices, and management challenges related to axSpA. Descriptive statistics were applied and normalized average scores were computed for ranking questions and converted into percentages. Data collection occurred between April and May 2021.

Results: A total of 188 responses were received and analyzed (response rate 50.6% during COVID pandemic). Most respondents were consultants (68.1%), practiced in tertiary governmental hospitals (52.7%) and located in urban settings (95.1%) (Table 1). A majority (88.6%) reported delayed presentation of axSpA patients, primarily due to low disease awareness among primary care physicians (55.8%) and absence of validated referral criteria (35.0%), Figure 1. Orthopedists, family physicians, and internists were among the top referring specialties. Nearly half of respondents believed that non-rheumatology specialists are reluctant to refer their axSpA patients to a rheumatologist.Diagnostic challenges were reported by 65.5% of respondents, especially in patients with atypical symptoms or limited access to HLA-B27 testing and advanced imaging. Only 28.8% experienced difficulty ordering or interpreting HLA-B27, primarily due to test unavailability (66.7%), or perceived low prevalence of HLA-B27 in their patient population (31%). The majority (76.6%) had access to a musculoskeletal radiologist to read X-rays and MRIs. Trust in radiology reports of sacroiliac X-rays and MRI for assessing suspected axSpA was generally moderate to high.Figure 2 illustrates the preferred frequency of monitoring various axSpA disease metrics across different time intervals, including those rarely or never used.About 47% and 31.5% of respondents reported difficulties in tracking patient-reported outcomes and physical exam findings, respectively—mainly due to busy schedule and lack of a nurse to support. In terms of management, patient non-adherence due to fear of drug side effects (44.1%) or symptom improvement (43.1%) were leading obstacles. Only 12% had access to a rheumatology-trained nurse. Physiotherapy was considered to be usually useful by 45.2% of rheumatologists.

Conclusion: This is the first comprehensive study from the Middle East and North Africa region to explore clinical practices and challenges in the referral, diagnosis, management, and monitoring of axSpA among rheumatologists. Delays in diagnosis and referral suggest the need for educational initiatives targeting non-rheumatologists, and improved multidisciplinary support.

Supporting image 1Table 1: Participants’ demographics

Supporting image 2Figure 1. Perceived challenges and referral patterns in axial spondyloarthritis care: (A) Delays in referral to rheumatology, (B) Specialties most frequently referring patients, (C) Reasons for referral reluctance from non-rheumatologists, and (D) Diagnostic challenges.

Supporting image 3Figure 2: Frequency of monitoring disease metrics perceived by rheumatologists


Disclosures: K. Alnaqbi: None; M. Alaswad: None; T. Al Araimi: None; A. Mahmoud: None; S. Al emadi: None; H. Al Rayyes: None; K. Mohammed: None; X. Barliakos: Abbvie, 1, 2, 5, Advanz, 1, 2, Alexion, 1, 2, Alfasigma, 1, 2, Amgen, 1, 2, Astra Zeneca, 1, 2, Bristol-Myers Squibb(BMS), 1, 2, Celltrion, 1, 2, 5, Cesas, 1, 2, Clarivate, 1, 2, Eli-Lilly, 1, 2, Galapagos, 1, 2, Janssen, 5, Johnson and Johnspn, 1, 2, Moonlake, 1, 2, 5, Novartis, 1, 2, 5, Peervoice, 1, 2, Pfizer, 1, 2, Roche, 1, 2, Sandoz, 1, 2, Springer, 1, 2, Stada, 1, 2, Takeda, 1, 2, UCB Pharma, 1, 2, Zuellig, 1, 2.

To cite this abstract in AMA style:

Alnaqbi K, Alaswad M, Al Araimi T, Mahmoud A, Al emadi S, Al Rayyes H, Mohammed K, Barliakos X. Practice Patterns and Barriers in the Referral, Management and Monitoring of Axial Spondyloarthritis: Insights from an Online Survey of Rheumatologists [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/practice-patterns-and-barriers-in-the-referral-management-and-monitoring-of-axial-spondyloarthritis-insights-from-an-online-survey-of-rheumatologists/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/practice-patterns-and-barriers-in-the-referral-management-and-monitoring-of-axial-spondyloarthritis-insights-from-an-online-survey-of-rheumatologists/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology